nuvalent is improving human health by developing breakthrough small molecule therapeutics that engage biological targets in new ways using cutting-edge chemical insights. by expanding the universe of targets that interact with small molecules, we are generating therapeutics with activities not previously possible, including modulation of ‘undruggable’ targets. our unique approach is leading to first-in-class and best-in-class small molecule therapeutics that will significantly impact patient’s lives.
![Nuvalent Inc - Ordinary Shares logo](/files/LOGO/1861560-NUVL.png)
Company profile
Ticker
NUVL
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Nuvalent Securities Corporation ...
NUVL stock data
Latest filings (excl ownership)
8-K
Other Events
22 Jul 24
8-K
Submission of Matters to a Vote of Security Holders
14 Jun 24
8-K
Other Events
16 May 24
10-Q
2024 Q1
Quarterly report
9 May 24
8-K
Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2024 Financial Results
9 May 24
ARS
2023 FY
Annual report to shareholders
26 Apr 24
DEFA14A
Additional proxy soliciting materials
26 Apr 24
DEF 14A
Definitive proxy
26 Apr 24
S-8
Registration of securities for employees
27 Feb 24
10-K
2023 FY
Annual report
27 Feb 24
Latest ownership filings
4
Emily Conley
16 Jul 24
4
Deborah Ann Miller
16 Jul 24
4
Henry E. Pelish
11 Jul 24
3
Henry E. Pelish
11 Jul 24
4
Deborah Ann Miller
10 Jul 24
144
Notice of proposed sale of securities
8 Jul 24
4
Darlene Noci
2 Jul 24
4
Alexandra Balcom
2 Jul 24
144
Notice of proposed sale of securities
1 Jul 24
144
Notice of proposed sale of securities
28 Jun 24
Financial summary
Quarter (USD) | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 98.52 mm | 98.52 mm | 98.52 mm | 98.52 mm | 98.52 mm | 98.52 mm |
Cash burn (monthly) | 78.96 mm | (no burn) | 17.53 mm | 14.32 mm | 12.03 mm | 9.28 mm |
Cash used (since last report) | 305.26 mm | n/a | 67.77 mm | 55.37 mm | 46.51 mm | 35.89 mm |
Cash remaining | -206.75 mm | n/a | 30.74 mm | 43.14 mm | 52.01 mm | 62.62 mm |
Runway (months of cash) | -2.6 | n/a | 1.8 | 3.0 | 4.3 | 6.7 |
Institutional ownership, Q1 2024
13F holders | Current |
---|---|
Total holders | 175 |
Opened positions | 80 |
Closed positions | 14 |
Increased positions | 40 |
Reduced positions | 41 |
13F shares | Current |
---|---|
Total value | 4.60 tn |
Total shares | 90.62 mm |
Total puts | 116.40 k |
Total calls | 837.90 k |
Total put/call ratio | 0.1 |
Largest owners | Shares | Value |
---|---|---|
Flynn James E | 25.48 mm | $0.00 |
Deerfield Management | 19.99 mm | $1.50 tn |
FMR | 8.79 mm | $660.41 bn |
Paradigm Biocapital Advisors | 4.18 mm | $313.71 bn |
Vanguard | 3.41 mm | $256.21 bn |
Perceptive Advisors | 2.78 mm | $209.01 bn |
BLK Blackrock | 2.71 mm | $203.38 bn |
Bain Capital Life Sciences Investors | 2.70 mm | $202.54 bn |
Bain Capital Life Sciences Fund II | 2.40 mm | $183.98 mm |
Fairmount Funds Management | 1.92 mm | $144.52 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
15 Jul 24 | Emily Conley | Class A Common Stock | Sell | Dispose S | No | Yes | 81.93 | 205 | 16.80 k | 2,507 |
15 Jul 24 | Emily Conley | Class A Common Stock | Sell | Dispose S | No | Yes | 81.4 | 2,195 | 178.67 k | 2,712 |
15 Jul 24 | Emily Conley | Class A Common Stock | Sell | Dispose S | No | Yes | 80.29 | 1,900 | 152.55 k | 4,907 |
15 Jul 24 | Emily Conley | Class A Common Stock | Sell | Dispose S | No | Yes | 79.43 | 700 | 55.60 k | 6,807 |
15 Jul 24 | Emily Conley | Class A Common Stock | Option exercise | Acquire M | No | Yes | 13.79 | 5,000 | 68.95 k | 7,507 |
15 Jul 24 | Emily Conley | Stock Option Class A Common Stock | Option exercise | Dispose M | No | Yes | 13.79 | 5,000 | 68.95 k | 26,667 |
12 Jul 24 | Deborah Ann Miller | Class A Common Stock | Sell | Dispose S | No | Yes | 80.16 | 6,000 | 480.96 k | 33,300 |
12 Jul 24 | Deborah Ann Miller | Class A Common Stock | Option exercise | Acquire M | No | Yes | 27.85 | 6,000 | 167.10 k | 39,300 |
12 Jul 24 | Deborah Ann Miller | Stock Option Class A Common Stock | Option exercise | Dispose M | No | Yes | 27.85 | 6,000 | 167.10 k | 96,154 |
9 Jul 24 | Henry E. Pelish | Class A Common Stock | Grant | Acquire A | No | No | 0 | 13,100 | 0.00 | 76,595 |
News
Nuvalent Begins Phase 1 Trial for New HER2-Selective Lung Cancer Treatment
22 Jul 24
Stifel Maintains Buy on Nuvalent, Raises Price Target to $115
10 Jul 24
Novavax And Agios Pharmaceuticals Were Among The 10 Biggest Mid-Cap Gainers Last Week (June 1-June 7): Are These In Your Portfolio?
9 Jun 24
Wedbush Reiterates Outperform on Nuvalent, Maintains $99 Price Target
17 May 24
Nuvalent Q1 2024 GAAP EPS $(0.69) Misses $(0.68) Estimate
9 May 24
Press releases
Nuvalent Announces First Patient Dosed in HEROEX-1 Phase 1a/1b Clinical Trial of NVL-330, its Novel HER2-selective Inhibitor
22 Jul 24
Nuvalent to Present Updated Data for ROS1-Selective Inhibitor, Zidesamtinib, and ALK-Selective Inhibitor, NVL-655, at the ESMO Congress 2024
16 Jul 24
Nuvalent Announces Promotion of Henry Pelish, Ph.D. to Chief Scientific Officer
11 Jul 24
Nuvalent to Participate in the 2024 Jefferies Global Healthcare Conference
29 May 24
Nuvalent Receives U.S. FDA Breakthrough Therapy Designation for NVL-655
16 May 24